Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.42 |
| ▸ | CSF1R | P07333 | 3/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26515870 | 0.83 | CRHR1 (0.47) | CRHR1CSF1RSYK | |
| SCHEMBL17815748 | 0.78 | ACHE (0.38) | ACHE | |
| SCHEMBL15906702 | 0.76 | ACHE (0.50) | CRHR1ACHE | |
| SCHEMBL10196592 | 0.73 | ACHE (0.49) | SYKACHELMNA | |
| SCHEMBL21256824 | 0.73 | CSF1R (0.39) | CSF1R | |
| SCHEMBL22965291 | 0.72 | KMT2A (0.45) | SYKACHELMNATHRB | |
| SCHEMBL6870169 | 0.72 | CSF1R (0.41) | CRHR1CSF1RTHRB | |
| SCHEMBL6874897 | 0.70 | CRHR1 (0.38) | CRHR1CSF1R | |
| SCHEMBL18330517 | 0.69 | SYK (0.46) | SYKACHELMNATHRB | |
| SCHEMBL171708 | 0.69 | ACHE (0.46) | CRHR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | ENYO PHARMA (FR) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | TST, TPMT, MMP1 | CRHR1 4331/4885CSF1R 3783/4885SYK 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.